Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or

Allergan Plc (AGN) NYSE

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]] [[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview as of [[ item.timeDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ fieldTitles[key] ]] [[ value ]] [[ value ]]
3-Month Performance
View Chart

Fundamentals

See More
  • Market Capitalization, $K 71,707,800
  • Shares Outstanding, K 395,950
  • Annual Sales, $ 15,071 M
  • Annual Income, $ 3,915 M
  • 36-Month Beta 1.01
  • Price/Sales 4.76
  • Price/Book 0.89

Price Performance

See More
Period Period Low Period High Performance
1-Month
184.50 +1.90%
on 11/23/16
224.98 -16.44%
on 11/09/16
-11.45 (-5.74%)
since 11/07/16
3-Month
184.50 +1.90%
on 11/23/16
248.49 -24.34%
on 09/15/16
-50.42 (-21.15%)
since 09/07/16
52-Week
184.50 +1.90%
on 11/23/16
317.48 -40.78%
on 12/30/15
-128.51 (-40.60%)
since 12/07/15

Most Recent Stories

More News
Teva Copaxone EU Label to Omit Pregnancy Contraindication

Teva Pharmaceutical Industries Ltd. (TEVA) announced that it has received a positive outcome to remove the pregnancy contraindication from the label of its key drug Copaxone in the EU.

Here's Why Teva Pharmaceutical's (TEVA) Stock Is Down Today

Shares of Teva Pharmaceutical Industries (TEVA) slipped over 5.8% in morning trading Tuesday after the company announced a change in upper-level management.

SHAREHOLDER ALERT - Bronstein, Gewirtz & Grossman, LLC Reminds Investors of Class Action Against Allergan PLC (AGN) and Lead Plaintiff Deadline: January 3, 2017

NEW YORK, NY / ACCESSWIRE / December 5, 2016 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a securities class action has been filed against Allergan PLC ("Allergan" or the "Company") (NYSE:...

Amgen/Allergan File for EU Approval of Avastin Biosimilar

Amgen Inc. (AMGN), along with partner Allergan plc. (AGN), announced the submission of a Marketing Authorization Application (MAA) to the European Medicines Agency (EMA) for ABP 215.

Allergan Announces Settlement of a DELZICOL® (mesalamine) Patent Litigation

Allergan plc (NYSE:AGN), a leading global pharmaceutical company, and its subsidiaries today announced that they, along with Qualicaps Co., Ltd., have reached a settlement regarding their litigation with...

Los Angeles Woman Files Lawsuit Against Plastic Surgeon and Device Manufacturer for Fraud

Los Angeles resident Wendy Knecht filed a lawsuit yesterday[11/28/16] in Los Angeles Superior Court alleging that her plastic surgeon, Max R. Lehfeldt, M.D., of Teleos Plastic Surgery, conspired with medical...

Top Research Reports for Alphabet, Deere & Bristol-Myers

Top Research Reports for Alphabet, Deere & Bristol-Myers

Pharma Stock Roundup: Lilly Alzheimer's Drug Fails, J&J in Acquisition Talks with ALIOF

Lilly's (LLY) stock was hit by the company's announcement that its investigational Alzheimer's disease drug failed in a late-stage study.

SHAREHOLDER ALERT: Brower Piven Encourages Investors Who Have Losses In Excess Of $100,000 From Investment In Allergan plc To Contact Brower Piven Before The Lead Plaintiff Deadline In Class Action Lawsuit - AGN

The securities litigation law firm of Brower Piven, A Professional Corporation, announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of...

Allergan PLC Investors With Losses In Excess of $1,000,000 Are Reminded to Contact the Rosen Law Firm Regarding the Important Deadline in Class Action filed by Firm - AGN

Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Allergan plc (NYSE- AGN) and/or Actavis plc between February 25, 2014 and November 3, 2016, both dates inclusive...

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strongest short term outlook on maintaining the current direction.

Longer term, the trend strength is Maximum. Long term indicators fully support a continuation of the trend.

See More

Business Summary

Allergan, Inc. is a healthcare company. It focuses on developing and commercializing pharmaceuticals, biologics, medical devices and over-the-counter products for the ophthalmic, neurological, medical aesthetics, medical dermatology, breast aesthetics, urological and other specialty markets. Allergan...

See More

Support & Resistance

2nd Resistance Point 194.17
1st Resistance Point 192.55
Last Price 189.36
1st Support Level 189.20
2nd Support Level 187.47

See More

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.